Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 May 1;81(1):e17-e21.
doi: 10.1097/QAI.0000000000001986.

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study

Barbara Rossetti  1   2 , Roberta Gagliardini  3 , Gaetana Sterrantino  4 , Vincenzo Colangeli  5 , Alessandra Latini  6 , Manuela Colafigli  6 , Francesca Vignale  7 , Stefano Rusconi  8 , Antonio Di Biagio  9 , Giancarlo Orofino  10 , Ivano Mezzaroma  11 , Vincenzo Vullo  12 , Daniela Francisci  13 , Claudio Mastroianni  14 , Michele Trezzi  15 , Benedetta Canovari  16 , Silvia Lamonica  2 , Arturo Ciccullo  2 , Alberto Borghetti  2 , Antonella DʼArminio Monforte  17 , Simona Di Giambenedetto  2 , Andrea De Luca  1   3 ; for GUSTA trial study group
Affiliations
Randomized Controlled Trial

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study

Barbara Rossetti et al. J Acquir Immune Defic Syndr. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

A.B. reports nonfinancial support from Bristol-Myers Squibb; personal fees from Gilead Sciences; and nonfinancial support from ViiV Healthcare. A.D.L. reports consulting fees from Gilead Sciences, Abbvie, Janssen, Bristol-Myers Squibb, ViiV Healthcare Italy, and Merck Sharp and Dohme, outside the submitted work. B.R. reports nonfinancial support from Janssen, ViiV Healthcare Italy, Abbvie, and Gilead and consulting fees from Merck Sharp and Dohme, outside the submitted work. A.D.M. reports grants and consulting fees from Bristol-Myers Squibb, Merck Sharp and Dohme, and Gilead and consulting fees from ViiV Healthcare Italy, outside the submitted work. C.M. reports consulting fees and nonfinancial support from ABBVIE; consulting fees from Merck Sharp and Dohme, Gilead Sciences, ViiV Healthcare Italy, and BMS; and nonfinancial support from ASTELLAS, outside the submitted work. F.V. reports nonfinancial support from Bristol-Myers Squibb, ViiV Healthcare Italy, and Gilead Sciences and consulting fees from Merck Sharp and Dohme and BMS, outside the submitted work. M.C. reports consulting fees from Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme, Bristol-Myers Squibb, and ViiV Healthcare Italy, outside the submitted work. I.M. reports grants and consulting fees from ViiV Healthcare Italy. S.R. reports grants and consulting fees from ViiV Healthcare Italy, Bristol-Myers Squibb, Merck Sharp and Dohme, Gilead Sciences, and Janssen, outside the submitted work. S.D.G. reports personal fees from Bristol-Myers Squibb, Janssen-Cilag, ViiV Healthcare Italy, Gilead, and Merck Sharp and Dohme, outside the submitted work. The remaining authors have no conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
A, APRI score during follow-up. B, FIB-4 during follow-up. No significant difference between arms at each time-point.
See this image and copyright information in PMC

References

    1. Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, et al. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One. 2013;8:e53992. - PMC - PubMed
    1. Friedman SL. Preface. Clin Liver Dis. 2008;12:xiii–xiv. - PubMed
    1. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119:1858–1870. - PMC - PubMed
    1. Berres ML, Koenen RR, Rueland A, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010;120:4129–4140. - PMC - PubMed
    1. Bruno R, Galastri S, Sacchi P, et al. Gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut. 2010;59:513–520. - PubMed

Publication types

MeSH terms

LinkOut - more resources